mptoms: consider re-initiating IGIV while discontinuing Hizentra (see full labeling). Thrombosis risk: give at minimum dose and/or infusion rate practicable.
Contraindications:
IgA-deficiency with antibodies against IgA and history of hypersensitivity. Hyperprolinemia (type I or II). Previous severe reaction to human immune globulin.
Warnings/Precautions:
Advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, cardiovascular disorders: increased risk of thrombosis. Ensure adequate hydration. Monitor for signs/symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. Diabetes mellitus, >65yrs, hypovolemia, sepsis, paraproteinemia: increase risk of renal dysfunction; monitor and consider lower, more frequent dosing. Correct volume depletion; assess renal function before and during therapy; discontinue if renal function deteriorates. Monitor for aseptic meningitis, hemolysis, delayed hemolytic anemia, transfusion-related acute lung injury (eg, respiratory distress, pulmonary edema, hypoxemia). Risk of transmission of blood-borne diseases. Pregnancy. Nursing mothers.
Pharmacological Class:
Immune globulin.
Interactions:
Concomitant nephrotoxic drugs: increased risk of renal toxicity. May affect response to live virus vaccinations. May interfere with serological test interpretation.
Adverse Reactions:
Local reactions (eg, swelling, redness, heat, pain, itching), headache, diarrhea, fatigue, back pain, nausea, pain in extremity, cough, upper RTI, rash, pruritus, vomiting, upper abdominal pain, migraine, arthralgia, pain, fall, nasopharyngitis; hypersensitivity reactions (discontinue if occurs).
How Supplied:
Single-use vial (5mL, 10mL, 20mL, 50mL)—1 |
